{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:29:58Z","timestamp":1786984198586,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ahjonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ahj.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T13:21:09Z","timestamp":1411910469000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial"],"prefix":"10.1016","volume":"169","clinical-trial-number":[{"clinical-trial-number":"nct00412984","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christopher B.","family":"Granger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cecilia","family":"Bahit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.09.006_bb0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2014.09.006_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.09.006_bb0015","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","volume":"61","author":"Patel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.09.006_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.09.006_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.09.006_bb0040","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1160\/TH10-07-0491","article-title":"New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs","volume":"104","author":"Garcia","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.09.006_bb0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2141.1996.d01-1499.x","article-title":"Rebound after cessation of oral anticoagulant therapy: the biochemical evidence","volume":"92","author":"Genewein","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ahj.2014.09.006_bb0050","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/STROKEAHA.110.611905","article-title":"Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence","volume":"42","author":"Broderick","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2014.09.006_bb0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"Fang","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2014.09.006_bb0060","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.ahj.2015.02.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000}}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031400564X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031400564X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T22:52:34Z","timestamp":1538175154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031400564X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S000287031400564X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.09.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725291301.793526306","asserted-by":"object"}]},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}